DDX11-AS1 modulates DNA damage repair to enhance paclitaxel resistance of lung adenocarcinoma cells

Pharmacogenomics. 2023 Feb;24(3):163-172. doi: 10.2217/pgs-2022-0121. Epub 2023 Feb 13.

Abstract

Aim: To investigate the influence of DDX11-AS1 on paclitaxel (PTX) resistance in lung adenocarcinoma (LUAD). Methods: LncRNA expression and functional enrichment analyses were processed via bioinformatics methods. DDX11-AS1 expression was detected via quantitative real-time PCR. Cell counting kit-8, colony formation, flow cytometry and comet assays were manipulated to measure cell proliferation, apoptosis, cell cycle and DNA damage repair, respectively. Western blot was used to assess DNA damage-related protein expression. Results: DDX11-AS1 was in a high expression status in LUAD, and could promote LUAD cell proliferation and PTX resistance, while suppressing cell apoptosis. DNA damage repairing ability was also modulated by the change of DDX11-AS1 expression. Conclusion: LncRNA DDX11-AS1 promotes DNA damage repair to enhance PTX resistance in LUAD.

Keywords: DDX11-AS1; DNA damage repair; lung adenocarcinoma; paclitaxel; resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung* / drug therapy
  • Adenocarcinoma of Lung* / genetics
  • Adenocarcinoma of Lung* / pathology
  • Cell Proliferation / genetics
  • DEAD-box RNA Helicases / genetics
  • DEAD-box RNA Helicases / metabolism
  • DNA Damage / genetics
  • DNA Helicases / genetics
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • MicroRNAs* / genetics
  • Paclitaxel / pharmacology
  • Paclitaxel / therapeutic use
  • RNA, Long Noncoding* / genetics

Substances

  • Paclitaxel
  • RNA, Long Noncoding
  • MicroRNAs
  • DDX11 protein, human
  • DNA Helicases
  • DEAD-box RNA Helicases